Niki BioSolutions Launches $1.4M ATM Program with Wainwright Amid Going-Concern Warning
NIKI is trading near its 52-week low of $4 (0.0% above the low).
Summary
Niki BioSolutions launched a $1.4M at-the-market offering through H.C. Wainwright, with a conflict-of-interest disclosure involving its largest shareholder and a qualified independent underwriter appointed to address it.
Key Events · Financing and Capital Events · NIKI
-
ATM Program Launched
Niki BioSolutions entered into an at-the-market sales agreement dated October 9, 2026 with H.C. Wainwright and Brookline Capital Markets to sell up to $1,396,000 of common stock from time to time.
-
Conflict of Interest Disclosed
Dr. Kira Sheinerman, the company's largest shareholder with 51.6% voting power and a director, is a managing director at Wainwright. Brookline Capital Markets is acting as a qualified independent underwriter under FINRA Rule 5121.
-
Commission and Terms
The selling manager receives a 3.0% commission on gross proceeds. The company also granted Wainwright a right of first refusal for future financings for 12 months.
-
Distressed Financial Position
The offering follows going-concern warnings disclosed in August 2026 and material weaknesses in financial controls disclosed in September 2026. The stock trades near its 52-week low of $4.00.
Analysis · NIKI · Industrial Applications And Services
Niki BioSolutions activated its $75M shelf registration with a $1.4M at-the-market offering through H.C. Wainwright. The deal carries a 3% commission and a notable conflict: Dr. Kira Sheinerman, the company's largest shareholder (51.6% voting power) and a director, is also a managing director at Wainwright. Brookline Capital Markets is serving as a qualified independent underwriter to address the FINRA Rule 5121 conflict. The company is trading near its 52-week low of $4.00, and the offering comes just weeks after going-concern warnings and material weakness disclosures. The ATM provides a small capital lifeline but adds selling pressure to an already distressed stock.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.2% of the 1631 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NIKI was trading at $4.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $4.00 to $24.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.